WoundSource Page Designs_White Papers small

Shining a Light on the Cost of Wound Care: How Point-of-Care Bacterial Imaging is Reducing Cost & Improving Care

Shining a Light on the Cost of Wound Care
 
By submitting your information through this form, you confirm that you agree to WoundSource's Privacy Policy, as well as sharing your information with any partners for marketing purposes. You can opt out at any time.
 

Chronic wounds affect approximately 6.5 million patients in the United States, at an annual cost of billions of dollars. Bacterial infection often complicates chronic wounds and is a major driver of wound care expenses. When bacterial burden is identified and quantified early, appropriate treatment can be instituted promptly, thus promoting a positive healing trajectory and reducing wound care costs.

This illustrated guide by MolecuLight discusses contributors to the high costs of wound care, including bacterial infection, and offers a solution. MolecuLight i:X is a handheld, point-of-care imaging device using fluorescence to detect bacterial wound infection accurately and rapidly and to guide wound assessment, targeted cleaning and debridement, and inform treatment decision-making and monitoring. In clinical studies of more than 500 patients, MolecuLight i:X was demonstrated to be beneficial.

Wound care professionals will appreciate the informative and well-referenced discussions of wound care costs and fluorescence in bacterial imaging, as well as case studies of MolecuLight i:X use in real-world clinical settings and tips for wound assessment in the current pandemic.

This white paper covers the following topics:

Bacterial infection as a driving factor in wound care costs
Mechanism of bacterial fluorescence
Cost equation for wound care
Bacterial detection at point-of-care with MolecuLight fluorescent imaging
MolecuLight as an invaluable resource for wound care screening, planning and treatment monitoring
Accurate wound assessment in the COVID-19 era

Sponsored by MolecuLight

Chronic wounds affect approximately 6.5 million patients in the United States, at an annual cost of billions of dollars. Bacterial infection often complicates chronic wounds and is a major driver of wound care expenses. When bacterial burden is identified and quantified early, appropriate treatment can be instituted promptly, thus promoting a positive healing trajectory and reducing wound care costs.

This illustrated guide by MolecuLight discusses contributors to the high costs of wound care, including bacterial infection, and offers a solution. MolecuLight i:X is a handheld, point-of-care imaging device using fluorescence to detect bacterial wound infection accurately and rapidly and to guide wound assessment, targeted cleaning and debridement, and inform treatment decision-making and monitoring. In clinical studies of more than 500 patients, MolecuLight i:X was demonstrated to be beneficial.

Wound care professionals will appreciate the informative and well-referenced discussions of wound care costs and fluorescence in bacterial imaging, as well as case studies of MolecuLight i:X use in real-world clinical settings and tips for wound assessment in the current pandemic.

This white paper covers the following topics:

Bacterial infection as a driving factor in wound care costs
Mechanism of bacterial fluorescence
Cost equation for wound care
Bacterial detection at point-of-care with MolecuLight fluorescent imaging
MolecuLight as an invaluable resource for wound care screening, planning and treatment monitoring
Accurate wound assessment in the COVID-19 era

Sponsored by MolecuLight

WoundSource
The World’s Definitive Source for Wound Care & Product Information